Polymer Based Nano-Formulation of Diindolylmethane with High Oral Bioavailability

Vsevolod Kiselev1, Eugenii Klinskiy2, Shengmin Lee4, Ekaterina Muyzhnek2, Alexander Semov2 and Valery Alakhov2*

1National Research Centre "Kurchatov Institute", Moscow, Russia
2Supratek Pharma Inc. Montreal, Quebec, Canada
3MiraxBioPharma, Moscow, Russia

Abstract

At the present, a high potential of 3,3’-diindolylmethane (DIM) as a new preventive and therapeutic agent in oncology is well established, due to its ability to target multiple components of cancer cell cycle regulation, survival and progression. However, a very low bioavailability of DIM remains the major challenge for its efficient development as novel medicine. In this work, we have developed a polymer based nano-formulation comprising a non-ionic block copolymer, Pluronic F127 that increases oral bioavailability of DIM by almost one order of magnitude, as compared to the presently marketed products such as crystalline DIM and BioResponse DIM. The pharmacokinetic parameters established in the present study revealed that AUC and Cmax of the new formulation dosed at 60 mg/kg were 7.06 ± 0.93 µg ∙ h/mL, and 3.08 ± 0.17 µg/mL, while in the case of crystalline DIM dosed at the same dose AUC and Cmax were 0.97 ± 0.08 µg ∙ h/mL, and 0.18 ± 0.02 µg/mL. BioResponse DIM showed AUC and Cmax of 1.05 ± 0.05 µg ∙ h/mL, and 0.22 ± 0.02 µg/mL, respectively.

Keywords: Diindolylmethane; Pluronic F127; Bioavailability

Introduction

Epidemiology studies demonstrate that dietary consumption of cruciferous vegetables, including broccoli, cauliflower and Brussels sprouts may provide protection from some chronic diseases, including several types of cancer [1]. Phytochemicals derived from cruciferous vegetables include indole-3-carbinol (I3C) and its condensation product, 3,3’-diindolylmethane (DIM). Because I3C in cell culture medium or in mammalian cells readily converted into DIM, most of the responses observed for I3C in vitro and in vivo have been related to DIM activity [1,2]. Anti-cancer properties of DIM are well-known [2,3]. It targets multiple components of cancer cell cycle regulation and survival, including Akt/NF-κB signalling, caspase activation, cyclin-dependent kinase activities, estrogen receptor signalling, and endoplasmic reticulum stress. DIM also inhibits invasion of cancer cells and tumour angiogenesis. It has been shown that DIM interacts and activates aryl hydrocarbon receptor (AhR) [4]. The AhR is a transcription factor, known primarily as a receptor for toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and some non-toxic ligands. AhR activation plays an important role in the chemopreventive effects of DIM. Specifically, it up-regulates gene expression of the detoxification Phase I enzyme CYP1A1 and the Phase II enzymes glutathione-S-transferase and oxireductases [2]. These enzymes accelerate the metabolism of genotoxic agents, either environmental or endogenous, thus preventing the development of carcinogen-induced tumors.

We have recently reported that DIM is a selective and potent inhibitor of cancer stem cells (CSCs) [5]. In a panel of cancer cell lines, DIM inhibited tumor sphere formation at the concentrations up to 300 times lower than concentrations required for growth inhibition of parental cell cultures as adherent culture. We also found that treatment with DIM overcomes chemoresistance of CSCs to conventional cytotoxic agents, such as paclitaxel, doxorubicin, and SN-38. Pre-treatment of tumors with DIM before implantation to mice significantly retarded the growth of primary tumors, in comparison with tumors formed by non-treated tumors.

The unique selectivity of DIM, with respect to CSCs and drug resistance, when combined together with its other well-known biological activities, offers a novel and powerful tool for cancer therapy and prevention. However, therapeutic utility of this compound is limited by its very low solubility and bioavailability [6], and new formulations with improved bioavailability are highly required to reach therapeutically meaningful levels of DIM in circulation. One of such formulation has been recently established and known as BR-DIM (BioResponse DIM) (BioResponse, LLC, Boulder, Co), oral formulation of DIM that exhibits 50% higher bioavailability compared to the crystalline compound. At the present, BD-DIM is in multiple clinical studies [6]. The concentrations of DIM required to suppress CSCs formation are in the close range to those achievable in human plasma, after oral dosing of the BR-DIM composition. However, a more efficient formulation with additionally increased oral bioavailability of the compound could help fully explore potential of DIM as pharmaceutical agent.

In this work, we have described a new composition of DIM that demonstrates a much greater oral bioavailability, as compared to both crystalline DIM and BR-DIM, and allow achieving close to 10-fold increase in systemic exposure of the compound [7]. The new formulation is based on non-ionic block copolymer, Pluronic F127 that is known as highly safe excipient, and is used in multiple pharmaceutical, nutritional and cosmetic products.

Materials and Methods

Reagents

DIM was purchased from Alexis Corporation, BR-DIM was...
purchased from BioResponse Inc.; Pluronic F127 was a kind gift from BASF Corporation.

Animals

Female Sprague-Dawley rats (250-350 g) were purchased from Charles River Canada Inc. (St. Constant, Quebec, Canada). The animals were kept three per cage with an air filter cover under light (12 h light/dark cycle, light on at 06:00) and temperature (22°C ± 1°C) controlled environment. All manipulations with the animals were performed under a sterilized laminar hood. The animals had ad libitum access to Purina mouse chow (Pro Lab PMH 4018, Trademark of Agway, Syracuse, New York) and water. The animal studies were conducted according to the “Guidelines for Care and Use of Experimental Animals”. The animals were fasted overnight and anesthetized, before perfusion starts.

Formulation preparation

The F127-DIM formulation was prepared by co-dissolving DIM and Pluronic F127 in ethanol, followed by evaporation of the solvent till dryness, and, finally by reconstituting the dry matrix in distilled water to the final concentrations of DIM and Pluronic F127 of 3 mg/ml and 20 mg/ml, respectively.

The control dosing solution of DIM was prepared by suspending 15 mg of DIM in 5 ml of 0.5% methyl cellulose in distilled water.

The BR-DIM (BioResponse DIM® 75) dosing solution was prepared by suspending the content of two Bioresponse DIM 75 capsules (150 mg) in 50 mL of distilled water. Therefore, all the dosing solutions contained 3 mg/mL DIM; they were administered immediately after the preparation.

Animal dosing and sampling

DIM formulations and control (non-formulated compound) were orally administered to groups of 6-8 week-old female rats (4 animals per group) by gavage at the dose of 60 mg/kg. After various time intervals (15, 30, 45 min, 1, 2, 4, and 6 h) post-dosing, the blood samples were collected. The rats were anesthetized by general inhalation of Isoflurane (Bimeta-MTC, Animal Health Inc. Cambridge, ON, Canada). The blood samples were collected from the jugular vein with the heparinised tube, and kept immediately on ice for 5 to 10 min. Blood was immediately centrifuged and plasma was separated. The plasma samples were immediately frozen in dry ice and stored at -80°C, until further use.

Sample extraction and analysis

The plasma samples were defrosted, centrifuged, and aliquots (100 µL) were transferred to plastic tubes and extracted twice with 750 µL of tret-butyl methyl for 2 min, each time by shaking on 180°C rotator. The samples were centrifuged at 10,000 rpm for 10 minutes. The supernatants were separated and transferred to glass tubes. The organic phase was evaporated in the stream of nitrogen at 50°C, until dryness. The dried samples were kept at -80°C before the HPLC analysis. The samples were dissolved firstly in 15 µL of acetonitrile, and then diluted with 85 µL of mobile phase. The aliquots of 20 µL were injected into HPLC for analysis.

The HPLC conditions were as following: C18 reversed phase column 50×4.6 mm, Symmetry/Shield 3.5 µm, column temperature 35°C, flow rate 1.5 ml/min, injection volume 20 µL, UV-detection at λ=280 nm, mobile phase: linear gradient of buffer B from 0-100%, buffer A: 5% acetonitrile 0.1% TFA, buffer B: 90% acetonitrile 0.1% TFA, run time 10 min.

The DIM concentrations were calculated from the area under the peak (AUP), by using calibration curve. The areas under the curves (AUC) were calculated by trapezoidal method.

Results and Discussion

Since aqueous solubility of DIM is very low, the formulation comprising DIM and Pluronic F127 was prepared by co-dissolving both compounds in ethanol, to allow for formation of molecular dispersion of the components. When the organic solvent was removed by evaporation, the resulted solid mass containing DIM and Pluronic F127 at the ratio of approximately 1:6.7, became soluble in water and formed transparent physically and chemically stable solutions, with DIM concentration of up to at least 3 mg/ml. These solutions were used for the animal dosing by oral gavage for pharmacokinetics studies.

Figure 1 shows the results of plasma pharmacokinetics comparative study of non-formulated DIM, BR-DIM and novel Pluronic F127-based DIM composition. Table 1 summarizes the calculated values of Cmax and AUC. The results illustrate considerably improved oral bioavailability of F127-DIM formulation, compared to that of the conventional crystalline form of DIM and BR-DIM. As seen from the presented results, BR-DIM provides only marginal improvement of DIM pharmacokinetics (about 1.08-fold increase in AUC and 1.22-fold in Cmax), while in the case of F127-DIM, a dramatic increase in bioavailability was observed (7.28-fold and 17.11-fold increase in AUC and Cmax, respectively).

Based on the above results, the pharmacological properties of the new F127-DIM formulation should allow a dramatic improvement of this natural compound and possibly open new ways of its use, as both nutritional agent and pharmaceutical product. Importantly, Pluronic F127 is a well-proven, generally safe excipient that is broadly used as inactive ingredient in multiple marketed products [8], which provide a strong assurance of safe margin of F127-DIM formulation, and its quick and efficient introduction into human studies. At the present, based on the above described results, a new product Cineton® is being developed for commercial application in multiple areas. Preliminary
results of the ongoing studies in healthy volunteers provide strong evidence of translationability of the results presented herein, in to the human patients.

References
1. Safe S, Papineni S, Chintharlapalli S (2008) Cancer chemotherapy with indo-3-carbinol, bis(3'-indoly)l methane and synthetic analogs. Cancer Lett 269: 326-338.

2. Weng JR, Tsai CH, Kulp SK, Chen CS (2008) Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262: 153-163.

3. Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, et al. (2011) Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res 728: 47-66.

4. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, et al. (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 24: 359-369.

5. Semov A, Iourtchenco L, Liu LF, Li S, Xu Y, et al. (2012) Diindolylmethane (DIM) selectively inhibits cancer stem cells. Biochem Biophys Res Commun 424: 45-51.

6. Banerjee S, Parasramka M, Sarkar FH (2012) Cellular molecular and biological insight into chemopreventive and therapeutic potential of 3,3'-diindolylmethane (DIM). Nutraceuticals and Cancer 111-134.

7. Kiselev VI, Vasilyeva IG (2011) A pharmaceutical composition for peroral administration of diindolylmethane. WO 2011/034465 A1.

8. Raymond CR, Paul JS, Paul JW, Ray R, Paul S, et al. (2003) Hand book of pharmaceutical excipients. (4th edn), Science and Practice, Royal Pharmaceutical Society of Great Britain, London, UK 447-450.

| Formulation | \( C_{\text{max}} \) [µg/mL] | Ratio \( C_{\text{max}} \) Form./Control | AUC\(_{\text{0-6h}}\) [µg ∙ h/mL] | Ratio AUC\(_{\text{0-6h}}\) Form./Control |
|-------------|-----------------|-------------------------------|-----------------|-----------------|
| Control     | 0.18 ± 0.02     | -                             | 0.97 ± 0.08     | -               |
| BR-DIM      | 0.22 ± 0.02     | p=0.207                       | 1.05 ± 0.05     | p=0.429         |
| F127-DIM    | 3.08 ± 0.17     | p<0.0001                      | 7.06 ± 0.93     | p=0.0006        |

*- p-values calculated by two-tailed t-test

Table 1: \( C_{\text{max}} \) and AUC\(_{0-6h}\) values calculated for the animals treated with Control (non-formulated crystalline DIM), BioResponse DIM (BR-DIM), and F127-DIM formulation (F127-DIM).